3. Drug Development / Big Data Analysis Solution for Biomarker Discovery and Evaluation
– Drug Development
Currently, big data and artificial intelligence technologies are being used throughout the entire cycle in the field of new drug development. Even in the field of drug repurposing, big data and artificial intelligence technologies are being used.
When developing new medical uses for drugs that failed in commercialization due to safety issues in the clinical steps or those that are already selling on the market, these types of technologies can reduce costs and shorten the development period.
The core of these technologies is the extraction of information by mining omics big data. The processing and analysis of various omics big data will be able to accelerate the development of new drugs.

– Prediction of Tumor Mutation Burden (TMB) / Neoantigens
Recently, cancer treatment methods based on immuno-oncology are emerging. Theragen Bio obtains data by sequencing the genome collected from the tumors of patients and discovers biomarkers that can suggest the most suitable treatment method for the patients using the data. With the prediction of tumor mutation burden (TMB), one of the biomarkers, customized treatment methods can be analyzed promptly and accurately.
The new cancer vaccine includes 10 to 20 different specific variation proteins and neoantigens by each tumor of a patient. These proteins are not found in healthy cells and play the role of enhancing the effect of T-cells on attacks on cancer cells. Therefore, it is critical to predict if this protein is present in a cell for effective vaccine treatment.

– Development and Evaluation of Biomarkers
If biomarkers for target drugs are discovered during drug development, the development success rate can be increased by classifying patients who react well to the drugs during clinical trials using the biomarkers. Theragen Bio provides such a service as part of its data-based solution business for customized treatments for patients.
